People
Murphy Named President CEO at Oragenics
24 June 2022 - - US-based biotechnology company Oragenics, Inc. (NYSE American: OGEN) has appointed Kimberly M. Murphy, member of the board of directors, as president and chief executive officer effective June 23, 2022, the company said.

Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the US and global launch of Merck's (NYSE: MRK) HPV/Gardasil Franchise.

Murphy joined Oragenics' board of directors in 2020.

Most recently Murphy served as vice president of the Influenza Franchise and Global Vaccine Commercialization Leader at GSK, with responsibility for the global influenza vaccines business and also served as vice president and Global Marketing Head for GSK's shingles vaccine, Shingrix.

Earlier Murphy was vice president and Lead for the North America Vaccines Integration Planning Team where she integrated GSK's acquisition of Novartis AG's vaccine division and served as vice president of US Vaccines Customer Strategy and as Senior director of US Influenza Portfolio Strategy. She also had distinguished vaccine leadership careers at Merck and Co., Inc. and Novartis.

Murphy currently serves as a director of Blue Water Vaccines, Inc. (NASDAQ: BWV) and as chairperson of Clarus Therapeutics Holdings Inc. (NASDAQ: CRXT).

She previously served in Board and advisory roles for a privately held vaccine development company, the biotechnology Industry Organization, the Biodefense Advisory Council and the Saint Joseph's University Pharmaceutical and Healthcare Marketing MBA Program.

Murphy holds a BA from Old Dominion University and an MBA from Saint Joseph's University, and completed the Marketing Excellence Program at the Wharton School of the University of Pennsylvania.

Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms.

Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus.

The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the National Institutes of Health and the National Research Council of Canada with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration.

Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.
Login
Username:

Password: